Answers are grounded in this paper and cite their sources.
Clinical study shows significant improvements in anatomy and function with faricimab in patients with nAMD and DME, indicating its effectiveness.
Faricimab demonstrated rapid and significant anatomical and functional improvements in 6-month real-world data, evident as early as 15 days after the initial injection, with a safety profile comparable to phase III trials. These findings support faricimab as a potent and reliable therapeutic option in the real-world management of nAMD and DME, though extended follow-up is needed to assess long-term outcomes.
No takes yet. Share an insight, caveat, or question.
ÇAKIR et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: